Screening methods

专利摘要:

公开号:AU2004252273A1
申请号:U2004252273
申请日:2004-06-25
公开日:2005-01-06
发明作者:Brian Anderton；Helen Byers；Diane Hanger；Malcolm Ward
申请人:Kings College London；Proteome Sciences PLC；
IPC主号:C12Q1-42

专利说明:
WO2005/001114 PCT/GB2004/002739 Screening Methods Field of the Invention The present invention relates to methods for screening 5 for substances capable of modulating the phosphorylation of tau protein, and in particular paired helical filament (PHF) tau, and the use of such modulators in the treatment of tauopathies. The assays and screening methods are based on the identification of new 10 phosphorylation sites in PHF tau and new kinases and combinations of kinases as therapeutic targets. Background of the Invention Alzheimer's disease (AD) is a neurodegenerative disease 15 characterised by the presence of senile plaques and neurofibrillary tangles in the brain. The degree of dementia at death correlates better with neurofibrillary tangle numbers than with senile plaques counts. The presence of neurofibrillary tangles in neurons results in 20 the death of those neurons, implying that prevention of tangle formation is an important therapeutic goal. The principal protein that forms the neurofibrillary tangle is the microtubule-associated protein, tau, which assembles into filaments that have the appearance of 25 twisting about each other in pairs and are referred to as paired helical filaments (PHF). PHF are present in different locations in degenerating neurons in the Alzheimer brain and when many aggregate in the neuronal cell body, they produce the neurofibrillary tangle (Lee 30 et al, 2001). Senile plaques have an extracellular central deposit of amyloid P-peptide (AP), which is surrounded by dystrophic neurites to form the senile or neuritic plaque. In vitro 1 WO2005/001114 PCT/GB2004/002739 and in vivo AP has been shown to be neurotoxic. AP is derived by proteolytic processing of the larger amyloid precursor protein (APP). Much attention has been focused on AP production as a therapeutic target because its 5 production is believed to be an early event in AD pathogenesis. This is because mutations in the APP gene, which give rise to autosomal dominant AD, result in either increased overall production of AP or in a relative increase in the slightly longer A3 42 over AP40, 10 the former being more amyloidogenic; AP 42 has two additional hydrophobic amino acids at the C-terminus of 40-residue A 40 thereby endowing the peptide with an increased tendency to aggregate and form amyloid fibres. Mutations in two other genes that also cause autosomal 15 dominant AD, presenilin-1 and presenilin-2 (PS1 & PS2) also result in an increase in the ratio of Ap 42 to AP40. The belief that AP deposition in the brain precedes the appearance of neurofibrillary tangles has been the basis of the amyloid cascade hypothesis but it has been 20 uncertain whether tangles are important in pathogenesis or are only an unimportant epiphenomenon. This has been changed by the discovery of mutations in the gene for tau in some other related neurodegenerative diseases. 25 The mechanism by which AP kills neurons in the brain has still to be established. Many studies of AP toxicity have been conducted in tissue culture using rat brain neuronal cultures. We have shown that exposure of both foetal rat and human brain neuronal cultures to 30 aggregated AP induces within 2 to 10 minutes increases in the phosphotyrosine content of several proteins but also including tau (Williamson et al 2002). We have also shown that this treatment results in activation of the 2 WO2005/001114 PCT/GB2004/002739 tyrosine kinase fyn, a member of the src family of tyrosine kinases. This tyrosine phosphorylation of tau was prevented by inhibitors of the src family of tyrosine kinases. 5 It has previously been reported that increased levels of fyn are associated with neurons containing abnormally phosphorylated tau in AD brain (Shirazi et al, 1993) and we have demonstrated using antibodies that recognise 10 phosphotyrosine that PHF-tau from AD brain contains phosphotyrosine (Williamson et al 2002). We have shown in vitro that fyn and Lck, both src family kinases, phosphorylate recombinant human tau and phosphotyrosines 18, 310 and 394 were positively identified in one or more 15 of their respective tryptic peptides, from sequence information of fragmented peptides. In addition, phosphotyrosine at position 197 was inferred from peptide masses in the survey scan (Scales et al, 2002). 20 Intraneuronal deposits of tau in the form of typical neurofibrillary tangles of AD or other morphologically distinct tau aggregates in a number of other neurodegenerative diseases, is the basis for grouping these conditions as tauopathies. Thus, in addition to 25 AD, the main examples of the tauopathies are frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy (PSP), Pick's disease, corticobasal degeneration, and multisystem atrophy (MSA). The intracellular tau 30 deposits (usually neuronal but can also be glial) are all filamentous and mostly in a hyperphosphorylated state compared to the level of phosphorylation of tau from control human brain. In the case of AD, this 3 WO2005/001114 PCT/GB2004/002739 hyperphosphorylated tau is often referred to as PHF-tau because it is derived from the PHF. Other than for AD, deposits of AP in the brain are either 5 absent or minimal in these other tauopathies. There are some tauopathy pedigrees with autosomal dominant disease in which the causative gene has been identified as the tau gene and although cases with the same mutation may present with apparently different diseases, they 10 invariably have tau deposits in the brain and are mostly of the FTDP-17 variety. Thus, the finding of mutations in the tau gene which result in disease and deposition of tau aggregates in neurons is compelling evidence for the primary pathogenic importance of tau deposition in all of 15 these conditions, including AD, whatever the primary cause of disease. Therefore, the amyloid cascade hypothesis is borne out by the discovery of tau mutations and confirms that indeed neurofibrillary tangle formation is almost certainly subservient to AP deposition in AD, 20 but that in the other tauopathies lacking AB deposits, then some other primary event must trigger the tau pathology. Tau abnormalities and deposition are therefore important therapeutic targets for all tauopathies, including AD. 25 Tau is a phosphoprotein, the function of phosphorylation remaining to be unequivocally established. However, increased phosphorylation of tau on multiple serine and threonine residues reduces the ability of tau to promote 30 microtubule assembly and to stabilise assembled microtubules, effects that have been demonstrated both in vitro and in cells. Many studies have shown that PHF-tau from AD brain is more heavily phosphorylated on serine and threonine than tau from control brain. This has been 4 WO2005/001114 PCT/GB2004/002739 demonstrated partly by protein sequencing and partly by demonstrating that certain monoclonal antibodies only label either PHF-tau or non-phosphorylated tau and not PHF-tau; the epitopes for many of these antibodies have 5 been mapped to particular phosphorylated residues present in PHF-tau and absent from control brain tau. The pathological tau from most other cases of other tauopathies seems to be similarly hyperphosphorylated to PHF-tau. 10 These findings strongly imply that similar abnormalities in regulating phosphorylation of tau are shared by all the tauopathies including AD. Since phosphorylation of proteins is effected by protein kinases and 15 dephosphorylation by protein phosphatases, identifying the protein kinases and phosphatases for tau is important because they are potentially therapeutic targets for these diseases. 20 It remains a considerable problem in the art in identifying the enzymes responsible for causing phosphorylation of paired helical filament tau and the sites phosphorylated by those enzymes. 25 Summary of the Invention Broadly, the present invention relates to the modulation of the phosphorylation of tau protein through its interaction with kinases and phosphatases. In particular, it is based on the identification of new 30 sites in tau protein that are susceptible to phosphorylation by kinases and to the identification of kinases and combinations of kinases that are capable of phosphorylating new and known phosphorylation sites in tau protein. Importantly, many of the newly identified 5 WO2005/001114 PCT/GB2004/002739 sites are present in paired helical filament (PHF) tau, and not in control tau or fetal tau. The present invention is based on the analysis by mass 5 spectrometry PHF-tau and tau from control adult and foetal rat brain, and identifies 12 new sites in PHF-tau, bringing the total to 37 phosphorylation sites (1 site is tyrosine 394 and the other 36 are either serine or threonine residues) and this with >90% sequence coverage. 10 Of these 12 sites, 11 have not been founrad in tau from normal human brain. A number of protein kinases have been demonstrated to phosphorylate tau in vitro, including glycogen synthase 15 kinase-3a (GSK-3a), glycogen synthase kiLnase-30 (GSK-3p), MAP kinases (ERKs 1 & 2), cdk5, cdc2 kinrase, JNK, several members of the SAP kinases (ly, 2a, 2b, 3, 4), p38MAP kinase, calmodulin-dependent kinase, protein kinase A (PKA), protein kinase C (PKC), casein kinase 1 (CK1), 20 casein kinase 2 (CK2), MARK, PKN, PKB, TTK, DYRK, Rho kinase and phosphorylase kinase. Of these kinases, GSK-3 has been demonstrated to phosphorylate the greatest number of identified sites in PHF-tau, this being 25 sites, including 2 sites that are generated by GSK-3 only 25 when tau is already phosphorylated and PKA phosphorylates 16 sites in PHF-tau. We have now shown also by in vitro phosphorylation that CK1 is also a candidate kinase for 6 of the 12 newly identified sites, GSK-3 phosphorylates 4 of these and PKA phosphorylates 2 of the new PHF-tau 30 sites. This brings the total number of sites in PHF-tau that can be phosphorylated by CK1 to 17 sites. The MAP kinases (ERKs 1 & 2), cdk5, cdc2 kinase, JNK, several members of the SAP kinases (ly, 2a, 2b, 3, 4), 6 WO2005/001114 PCT/GB2004/002739 and p38MAP kinase are similar in specificity to GSK-3, being essentially proline-directed protein kinases and they all phosphorylate most of the sites phcDsphorylated by GSK-3. Thus, after these proline-directed protein 5 kinases, CK1 is now the most conspicuous kinase as a candidate for contributing to generating the phosphorylation state of PHF-tau, with only 18 CK1 sites definitely shared by GSK-3. Therefore, of the 36 ser/thr sites in PHF-tau, 31 could potentially be phosphorylated 10 by a combination of GSK-3, CK1, and PKA, and the additional 5 sites remain as orphan sites with no kinase known to phosphorylate these residues. It is possible that GSK-3, CK1 or PKA could phosphorylate some or all of these orphan sites or indeed that one or more of the 15 other potential tau kinases listed above could be responsible and the phosphorylated sites have not been detected. However, the data disclosed herein imply that CK1 should be considered as a strong candidate for generating hyperphosphorylated tau in AD and the other 20 tauopathies and hence is a potential therapeutic target. Of the known phosphorylation sites in PHF-tau, several are considered to be particularly important- Monoclonal antibody, AT100, of all such antibodies is the most 25 specific for PHF-tau since it does not recognise normal brain tau nor foetal tau; as such it is considered to be diagnostic for pathological hyperphosphorylated tau in the tauopathies. The AT100 epitope requires phosphorylation of both T212 and S214. It is known that 30 T212 and S214 can be phosphorylated by GSK-3 and it has been reported that phosphorylation T212 by GSK-3 primes tau for phosphorylation at S214 by PKA (Singh et al, 1995a,b). We have found that CK1 is also able to 7 WO2005/001114 PCT/GB2004/002739 phosphorylate S214, thereby further implicating CK1 in pathological phosphorylation. One other site in tau, S262, has been shown to be 5 important in regulating the binding of tau to microtubules such that phosphorylation causes dissociation of tau. A novel kinase, MARK, that phosphorylates tau at this site was isolated from brain and proposed as the responsible kinase. We have found 10 that CKI is also able to phosphorylate S262 and S356, the latter being an homologous residue that may behave like S262 in contributing to regulating binding of tau to microtubules and we have found that both S262 and S356 are phosphorylated in PHF-tau. 15 Thus, the above two classes of phosphorylation of tau that are considered to be important could be regulated by CK1. Furthermore, it has been reported that CKI, particularly the CK618 isoform, is elevated in brain 20 extracts from AD cases compared to controls, which adds to the potential importance of CKI in pathogenesis (Ghoshal et al, 1999). With respect to tyrosine phosphorylation, PHF-tau is 25 phosphorylated on tyrosine 394 and fyn is the strongest candidate although other src family kinases may also phosphorylate tau in brain. Accordingly, in one aspect, the present invention 30 proposes that CKI is a novel therapeutic target for treating AD and other related tauopathies. In a further aspect, the present invention proposes that fyn and related src family kinases are novel therapeutic 8 WO2005/001114 PCT/GB2004/002739 targets for treating AD and other related tauopathies, in particular for tyrosine phosphor-ylation sites disclosed herein. 5 In a further aspect, the present invention proposes new phosphorylation sites in tau protein for use in screening for inhibitors of phosphorylation or promoters of dephosphorylation, optionally used in combination with the kinases identified herein as being capable of 10 phosphorylating the sites. As a consequence of these findings, the new sites and kinases can be used as the basis of assays and assay methods for screening for modulators of the 15 phosphorylation of the sites in tau protein for use or development as therapeutics for the treatment of tauopathies. Preferred modulators are capable of inhibiting the phosphorylation of tau to produce a phosphorylated state similar or identical to that of PHF 20 tau and/or promoting the dephosphorylation of phosphorylated forms of PHF-tau. Eleven of the new phosphorylation sites in tau protein are shown in Table 2 in red type in the left hand column. 25 They are the serine and threoniae residues at positions S68, T69, T71, (T111/S113), S191, S258, S289, (T414/S416), T427, S433 and S435 . A further tyrosine site at position 394 (Y394) has also been identified (e.g. phosphorylated by tyrosine kinases and 30 dephosphorylated by tyrosine phosphatases) . Of the 12 sites, 10 are only found in PHF-tau, see Table 2 comparing the PHF tau and control tau columns. 9 WO 2005/001114 PCT/GB2004/002739 Accordingly, in a further aspect, the present invention provides the use of a tau protein comprising one or more of these phosphorylation sites as defined herein for screening for candidate substances which are capable of 5 inhibiting phosphorylation at the site(s) by a kinase or promoting dephosphorylation of a phosphorylated site by a phosphatase. In the present invention, the tau protein comprising the 10 phosphorylation sites may be substantially full length and/or wild type tau or PHF-tau protein, or may be a fragment, active portion or sequence variant thereof. In other embodiments, the present invention may employ a corresponding nucleic acid molecule encoding the tau 15 protein. Where a tau protein which is a fragment, active portion or sequence variant is employed, the phosphorylation site(s) may be pr-esent with surrounding amino acids from the tau protein sequence. Preferably, the present invention employs PHF-tau protein. In the 20 present invention the numbering of tau and PHF-tau is according to the sequence of the longest brain isoform of human tau (441 amino acids) disclosed in Goedert et al (1989) EMBO J. 1989 Feb;8(2):393-9. Cloning and sequencing of the cDNA encoding an isoform of 25 microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA; or Goedert M, Jakes R. (1990) Expression of separate isoforms of human tau protein: correlation 30 with the tau pattern in brain and effects on tubulin polymerization. EMBO J., 9, 4225-30. Alternatively or additionally, any of the above defined tau proteins may possess phosphorylation at one or more 10 WO 2005/001114 PCT/GB2004/002739 of the phosphorylation sites. This enables the effects of cooperative phosphorylation of the protein to be studied, that is, where the phosphorylation of one site is dependent in changes to the tau protein caused by one 5 or more preceding or simultaneous phosphorylation steps. Thus, in some embodiments of the present invention, the tau protein may include one or more of the kncwn tau phosphorylation sites, for example those set out in Table 2, left hand column in black type, in addition to one or 10 more of the newly found sites, and optionally have phosphorylation at one or more of those additional sites. In a further aspect, the present invention provides a method of screening for substances which are capable of 15 inhibiting phosphorylation at one or more of the site(s) of a tau protein by a kinase, wherein the tau protein comprises one or more phosphorylation sites disclosed herein, the method comprising: (a) contacting at least one candidate substance, 20 the tau protein as defined herein and a kinase which is capable of phosphorylating the tau protein under conditions in which the kinase is capable of phosphorylating the site(s) of the tau protein in the absence of the candidate substance; 25 (b) determining whether, and optionally the extent to which, the candidate substance inhibits the phosphorylation of the tau protein at one or more sites of the tau protein; and, (c) selecting the candidate substance which 30 inhibits phosphorylation of the tau protein at one or more of the sites. In a further aspect, the present invention prcvides a method of screening for substances which are capable of 11 WO 2005/001114 PCT/GB2004/002739 promoting dephosphorylation at one or more of the site(s) of a tau protein by a phosphatase, wherein the tau protein comprises one or more sites as defined herein, the method comprising: 5 (a) contacting at least one candidate substance, the tau protein as defined herein and a phosphatase which is capable of dephosphorylating the tau protein under conditions in which the phosphatase is capable of dephosphorylating the site(s) of the tau protein in the 10 absence of the candidate substance; (b) determining whether, and optionally the extent to which, the candidate substance promotes the dephosphorylation of the tau protein at one or more sites of the tau protein; and, 15 (c) selecting the candidate substance which promotes dephosphorylation of the tau protein at one or more of the sites. In some embodiments, the method may comprise, having 20 identified a candidate substance according to one of the methods disclosed herein, the further step(s) of optimising the candidate substance to improve one or more of its properties and/or formulating it as a pharmaceutical. 25 In the methods and uses disclosed herein, preferably the kinase is selected from casein kinase 1 (CKI), casein kinase 2 (CK2), protein kinase A (PKA), glycogen synthase kinase 3a (GSK-3a), and glycogen synthase kinase 30 (GSK 30 31). More preferably, the kinase is CK1 or a combination (either simultaneously or sequentially applied) of CK1, PKA and GSK-30. 12 WO 2005/001114 PCT/GB2004/002739 In the present invention, preferably the step of detecting the presence and extent of phosphorylation and dephosphorylation in the tau protein can be carried out using mass spectroscopy as described in detail below. 5 Alternatively, or additionally, site specific recognition agents which are capable of distinguishing between a site which is phosphorylated and one which is not may be used. Examples of such agents known in the art are site specific antibodies such as monoclonal antibody AT100. 10 In a further aspect, the present invention provides a substance obtainable from one of the methods disclosed herein which is capable of inhibiting the phosphorylation or promoting the dephosphorylation of a tau protein at 15 one or more of the above defined sites. A further aspect of the present invention is based on the finding that casein kinase 1 is capable of phosphorylating a tau protein at previously unknown 20 positions. Some of the positions are known or suspected in the art of -being phosphorylation sites, while others are among the phosphorylation sites identified herein for the first time. The sites of PHF-tau protein that are phosphorylated by CKI include (S46/T50), S113, S131, 25 T149, T169, S184, S208, (S210/T212), S214, S237, S238, S241, S258, S262, T263, S285, S289, S305, S341, S352, S356, T361, T373, T386, (S412/S413/T414/S416 -two of these four), S416, S433 and S435. Of these sites, S113, 184, 208, (210/212), 214, 237, 238, S258, S289, S433 and 30 S435 are disclosed as phosphorylation sites of PHF-tau protein for the first time herein. The sequence of casein kinase 1 is provided in J Biol Chem. 1993 Mar 25;268(9):6394-401. Molecular cloning, expression, and characterization of a 49-kilodalton casein kinase I 13 WO 2005/001114 PCT/GB2004/002739 isoform from rat testis. Graves PR, Haas DW, Hagedorr CH, DePaoli-Roach AA, Roach PJ. Accordingly, the present invention provides the use of a 5 casein kinase 1 as defined herein (including fragments, active portions or sequence variants), or a corresponding nucleic acid molecule, for screening for candidate compounds which are capable of (a) inhibiting the activity of casein kinase 1 in phosphorylating a tau 10 protein such as paired helical filament tau or (b) binding to casein kinase 1 to inhibit its interaction with a tau protein such as paired helical filament tau. In a further aspect, the present invention provides a 15 method of screening for substances which are capable of inhibiting the phosphorylation of a tau protein by casein kinase 1 (CKI), wherein the tau protein comprises one or more phosphorylation sites disclosed herein, the method comprising: 20 (a) contacting at least one candidate substance, the tau protein as defined herein and casein kinase L under conditions in which the casein kinase 1 is capable of phosphorylating the site(s) of the tau protein in the absence of the candidate substance; 25 (b) determining whether, and optionally the extent to which, the candidate substance inhibits the phosphorylation of the tau protein at one or more sites of the tau protein by casein kinase 1; and, (c) selecting the candidate substance which 30 inhibits phosphorylation of the tau protein at one or more of the sites. In a further aspect, the present application also discloses that a combination of kinases is required to 14 WO2005/001114 PCT/GB2004/002739 phosphorylate the majority of the phosphorylation sites disclosed herein or in the prior art. In the experiments disclosed herein, a combination of casein kinase 1 (CK1) protein kinase A (PKA) and glycogen sEynthase kinase 3P 5 (GSK-3) was found to be capable, either alone or in cooperation, of phosphorylating the majority of the phosphorylation sites of tau protein and in particular PHF-tau protein. This combination of kinases can be used simultaneously or sequentially to screen for modulators 10 of tau phosphorylation, in contrast to prior art proposals that have focussed on screening using a single kinase. Accordingly, the present invention provides the use of a 15 casein kinase 1 (CKl), protein kinase A (PKA) and glycogen synthase kinase 3P (GSK-3) (including fragments, active portions or sequence variants), or a corresponding nucleic acid molecule, for screening for candidate compounds which are capable of (a) inhibiting 20 the activity of casein kinase 1 in phosphorylating a tau protein or (b) binding to casein kinase 1 to inhibit its interaction with a tau. In a further aspect, the present invention provides a 25 method of screening for substances which are capable of inhibiting the phosphorylation of a tau protein by casein kinase 1 (CK), protein kinase A (PKIG) and glycogen synthase kinase 3P (GSK-3p), wherein the tau protein comprises one or more phosphorylation sites disclosed 30 herein, the method comprising: (a) contacting at least one candidate substance, the tau protein as defined herein and casein kinase 1 (CK1), protein kinase A (PKA) and glycogen synthase 15 WO 2005/001114 PCT/GB2004/002739 kinase 33 (GSK-33) under conditions in which the kinases are capable of phosphorylating the site(s) of the tau protein in the absence of the candidate substance; (b) determining whether, and optionally the extent 5 to which, the candidate substance inhibits the phosphorylation of the tau protein at one or more sites of the tau protein by the kinases; and, (c) selecting the candidate substance which inhibits phosphorylation of the tau protein at one or 10 more of the sites. In this aspect of the invention, one or more of these kinases may be substituted by a kinase having the same or a similar activity and/or substrate specificity. 15 Embodiments of the present invention will now be discussed in more detail by way of example and not limitation with reference to the accompanying tables. 20 Tables Table 1 summarises the new sites found in the work leading to the present invention and the kin-ases capable of acting at those sites. Tables 2 and 3 present this data in more detail. 25 SEQ ID NO: 1 shows the amino acid sequence of rat casein kinase 1, a 428 amino acid protein. SEQ ID NO: 2 shows the amino acid sequence of the long 30 form of human tau protein, a 441 amino acid protein. SEQ ID NO: 3 shows the amino acid sequence of human fyn kinase, a 537 amino acid protein. 16 WO 2005/001114 PCT/GB2004/002739 Detailed Description Tau proteins The assays and assay methods disclosed hereinr can employ wild-type or full length tau proteins, kinases or 5 phosphatases or fragments, active portions or derivatives thereof. In the case of tau proteins, the materials used in the assays may be unphosphorylated or partially phosphorylated as discussed above. 10 In the present invention, derivatives of the tau proteins, kinases (especially CK1 kinase or fyn kinase) or phosphatases have an amino acid sequence which differs by one or more amino acid residues from the wild-type amino acid sequence, by one or more of addition, 15 insertion, deletion and substitution of one or more amino acids. Thus, variants, derivatives, alleles, mutants and homologues, e.g. from other organisms, are included. Thus, a derivative of tau protein or CK1 kinase or fyn kinase may include 1, 2, 3, 4, 5, greater than 5, or 20 greater than 10 amino acid alterations such as substitutions with respect to the wild-type sequence. Preferably, a fragment or derivative of a protein used in the assays disclosed herein preferably shares sequence 25 identity with the corresponding portion of the relevant wild-type sequence of the protein, and preferably has at least about 60%, or 70%, or 75%, or 80%, or 85%, 90% or 95% sequence identity. As is well-understood, identity at the amino acid level is generally in terms of amino 30 acid identity which may be defined and determined by the TBLASTN program, of Altschul et al. (1990) J. Mol. Biol. 215: 403-10, which is in standard use in the art. Identity may be over the full-length of the relevant peptide or over a contiguous sequence of about 5, 10, 15, 17 WO 2005/001114 PCT/GB2004/002739 20, 25, 30, 35, 50, 75, 100 or more amino acids, compared with the relevant wild-type amino acid sequence. Alternatively, nucleic acid encoding a fragment or derivative may hybridise to the corresponding wild type 5 nucleic acid under stringent conditions, for example as disclosed in textbooks such as Ausubel, Short Protocols in Molecular Biology, 1992 or Sambrook et al, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989, using a hybridization solution 10 comprising: 5X SSC, 5X Denhardt's reagent, 0.5-1.0% SDS, 100 pg/ml denatured, fragmented salmon sperm DNA, 0.05% sodium pyrophosphate and up to 50% formamide. Hybridization is carried out at 37-42 0 C for at least six hours. Following hybridization, filters are washed as 15 follows: (1) 5 minutes at room temperature in 2X SSC and 1% SDS; (2) 15 minutes at room temperature in 2X SSC and 0.1% SDS; (3) 30 minutes-1 hour at 37 0 C in 1X SSC and 1% SDS; (4) 2 hours at 42-65oC in 1X SSC and 1% SDS, changing the solution every 30 minutes. 20 One common formula for calculating the stringency conditions required to achieve hybridization between nucleic acid molecules of a specified sequence homology is (Sambrook et al., 1989): 25 Tm = 81.5 0 C + 16.6Log [Na+] + 0.41(% G+C) - 0.63 (% formamide) - 600/#bp in duplex As an illustration of the above formula, using [Na+] = [0.368] and 50% formamide, with GC content of 42% and an 30 average probe size of 200 bases, the Tm is 57 0 C. The Tm of a DNA duplex decreases by 1 - 1.5 0 C with every 1% decrease in homology. Thus, targets with greater than about 75% sequence identity would be observed using a hybridization temperature of 42oC. Such a sequence would 18 WO 2005/001114 PCT/GB2004/002739 be considered substantially homologous to the nucleic acid sequence of the present invention. Methods of Screening for Inhibitors ard Enhancers 5 It is well known that pharmaceutical research leading to the identification of a new drug may involve the screening of very large numbers of candidate substances, both before and even after a lead compound has been found. This is one factor which makes pharmaceutical research very 10 expensive and time-consuming. Means for assisting in the screening process can have considerable commercial importance and utility. As detailed above, methods of screening for a substance 15 which are inhibitors of phosphorylatiocn of tau protein or promoters of dephosphorylation of tau protein can be carried out by contacting one or more test substances with the tau protein and kinase or phosphatase (as defined herein) in a suitable reaction medium, and determining the 20 presence or extent of phosphorylation of dephosphorylation in the presence and absence of the candidate substance. A difference in activity in the presence and absence of the candidate substance is indicative of a modulating effect. 25 Preliminary assays in vitro may be followed by, or run in parallel with, in vivo assays. Of course, the person skilled in the art will design any appropriate control experiments with which to compare 30 results obtained in test assays. Performance of an assay method according to the present invention may be followed by isolation and/or manufacture and/or use of a compound, substance or molecule which 19 WO 2005/001114 PCT/GB2004/002739 tests positive for ability to modulate interaction between one of the phosphorylation sites of tau protein (as defined herein) and a kinase (such as CKI or a combination of CK1, PKA and GSK-33) or a phosphatase. 5 The precise format of an assay of the invention may be varied by those of skill in the art using routine skill and knowledge. For example, interaction between substances may be studied in vitro by labelling one with 10 a detectable label and bringing it into contact with the other which has been immobilised on a solid support. Suitable detectable labels, especially for peptidyl substances include 35 SS-methionine which may be incorporated into recombinantly produced peptides and 15 polypeptides. Recombinantly produced peptides and polypeptides may also be expressed as a fusion protein containing an epitope which can be labelled with an antibody. 20 The protein which is immobilized on a solid support may be immobilized using an antibody against that protein bound to a solid support or via other technologies which are known per se. A preferred in vitro interaction may utilise a fusion protein including glutathione-S 25 transferase (GST). This may be immobilized on glutathione agarose beads. In an in vitro assay format of the type described above a test compound can be assayed by determining its ability to diminish the amount of labelled peptide or polypeptide which binds to the 30 immobilized GST-fusion polypeptide. This may be determined by fractionating the glutathione-agarose beads by SDS-polyacrylamide gel electrophoresis. Alternatively, the beads may be rinsed to remove unbound protein and the amount of protein which has bound can be 20 WO 2005/001114 PCT/GB2004/002739 determined by counting the amount of label present in, for example, a suitable scintillation counter. The amount of a candidate substance which may be added to 5 an assay of the invention will normally be determined by trial and error depending upon the type of compound used. Typically, from about 0.001 nM to 1mM or more concentrations of putative inhibitor compound may be used, for example from 0.01 nM to 100pM, e.g. 0.1 to 50 10 pM, such as about 10 pM. Greater concentrations may be used when a peptide is the test substance. Even a molecule which has a weak effect may be a useful lead compound for further investigation and development. 15 Combinatorial library technology provides an efficient way of testing a potentially vast number of different substances for ability to modulate activity of a polypeptide. Such libraries and their use are known in the art. Compounds which may be used may be natural or 20 synthetic chemical compounds used in drug screening programmes. Extracts of plants which contain several characterised or uncharacterised components may also be used. 25 Antibodies directed to the site of interaction in either protein form a further class of putative inhibitor compounds. Candidate inhibitor antibodies may be characterised and their binding regions determined to provide single chain antibodies and fragments thereof 30 which are responsible for disrupting the interaction. Antibodies may also be employed as site specific recognition agents for determining whether phosphorylation of a site in tau protein has occurred during an assay. 21 WO 2005/001114 PCT/GB2004/002739 Antibodies may be obtained using techniques which are standard in the art. Methods of producing antibodies include immunising a mammal (e.g. mouse, rat, rabbit, 5 horse, goat, sheep or monkey) with the protein or a fragment thereof. Antibodies may be obtained from immunised animals using any of a variety of techniques known in the art, and screened, preferably using binding of antibody to antigen of interest. For instance, LO Western blotting techniques or immunoprecipitation may be used (Armitage et al., 1992, Nature 357: 80-82). Isolation of antibodies and/or antibocdy-producing cells from an animal may be accompanied by a step of sacrificing the animal. -5 As an alternative or supplement to iramunising a mammal with a peptide, an antibody specific for a protein may be obtained from a recombinantly produced library of expressed immunoglobulin variable dormains, e.g. using 0 lambda bacteriophage or filamentous bacteriophage which display functional immunoglobulin birding domains on their surfaces; for instance see WO 92/01047. The library may be naive, that is constructed from sequences obtained from an organism which has nrot been immunised 5 with any of the proteins (or fragments), or may be one constructed using sequences obtained from an organism which has been exposed to the antigen of interest. Antibodies according to the present invention may be 0 modified in a number of ways. Indeed the term "antibody" should be construed as covering any binding substance having a binding domain with the required specificity. Thus the invention covers antibody fragments, derivatives, functional equivalents and homologues of 22 WO 2005/001114 PCT/GB2004/002739 antibodies, including synthetic molecules and molecules whose shape mimicks that of an antibody enabling it to bind an antigen or epitope. 5 Example antibody fragments, capable of binding an antigen or other binding partner are the Fab fragment consisting of the VL, VH, C1 and CHI domains; the Fd fragment consisting of the VH and CHI domains; the Fv fragment consisting of the VL and VH domains of a single arm of an 10 antibody; the dAb fragment which consists of a VH domain; isolated CDR regions and F(ab')2 fragments, a bivalent fragment including two Fab fragments linked by a disulphide bridge at the hinge region. Single chain Fv fragments are also included. 15 A hybridoma producing a monoclonal antibody according to the present invention may be subject to genetic mutation or other changes. It will further be understood by those skilled in the art that a monoclonal antibody can be 20 subjected to the techniques of recombinant DNA technology to produce other antibodies or chimeric molecules which retain the specificity of the original antibody. Such techniques may involve introducing DNA encoding the immunoglobulin variable region, or the complementarity 25 determining regions (CDRs), of an antibody to the constant regions, or constant regions plus framework regions, of a different immunoglobulin. See, for instance, EP 0 184 187 A, GB 2 188 638 A or EP 0 239 400 A. Cloning and expression of chimeric antibodies are 30 described in EP 0 120 694 A and EP 0 125 023 A. Hybridomas capable of producing antibody with desired binding characteristics are within the scope of the present invention, as are host cells, eukaryotic or 23 WO 2005/001114 PCT/GB2004/002739 prokaryotic, containing nucleic acid encoding antibodies (including antibody fragments) and capable of their expression. The invention also provides methods of production of the antibodies including growing a cell 5 capable of producing the antibody under conditions in which the antibody is produced, and preferably secreted. The reactivities of antibodies on a sample may be determined by any appropriate means. Tagging with 10 individual reporter molecules is one possibility. The reporter molecules may directly or indirectly generate detectable, and preferably measurable, signals. The linkage of reporter molecules may be directly or indirectly, covalently, e.g. via a peptide bond or non 15 covalently. Linkage via a peptide bond may be as a result of recombinant expression of a gene fusion encoding antibody and reporter molecule. The mode of determining binding is not a feature of the present invention and those skilled in the art are able to choose 20 a suitable mode according to their preference and general knowledge. Mass Spectroscopy An LC/MS/MS based strategy was used to discover new 25 phosphorylation sites within tau protein isolated from AD brain. So called PHF-tau was initially extracted from a heat-stable preparation of human AD brain material and subsequently further purified by ion exchange chromatography. Having been separated using SDS-PAGE, 30 phospho-peptide mapping was then undertaken. Coomassie stained bands are excised, reduced, alkylated and enzymatically digested using a suite of proteases such as trypsin, chymotrypsin and endoproteinase Asp-N. Resulting peptide mixtures are then analysed by LC/MS/MS 24 WO 2005/001114 PCT/GB2004/002739 using a Q-TOF micro instrument with peptide separation achieved using a 75 micron ID PepMap reversed phase column with peptides eluted using a gradient of acetonitrile at a flowrate of 5 200nl/min. Database searching against bespoke index files is performed utilising the Mascot algorithm (Matrix Science). All MS/MS spectra relating to phosphopeptides 10 are then subsequently visually verified to check the result. Tandem MS/MS of peptides may be used to provide sequence information by virtue of the fragment ions produced. 15 Fragmentation occurs generally across the peptide bond leading to a ladder of sequence ions that are diagnostic of the amino acid sequence. The difference between consecutive ions in a series indicates the mass of the amino acid at that position in the peptide. The most 20 common ion types are b and y ions. The C-terminal containing fragments are designated y-ions and the N terminal containing fragments are designated b-ions (Roepstorff, P., Fohlman, J. J. Biomed. Mass Spectrom. 1984, 11, 601). Peptides created by trypsin proteolysis 25 and ionised by electrospray generally form ions that are doubly charged. This stems from the presence of basic groups within the peptide, namely, the alpha amino group at the N-terminus and the side chain of the C-terminal lysine or arginine. MS/MS spectra of such peptides 30 generally yield a prominent y-type ion series in the high mass end of the spectrum (Bonner, R., Shushan, B. Rapid Commun. Mass Spectrom. 1995, 9, 1067-1076). Ideally, for de novo sequencing purposes, a complete set of complementary b and y ions will ensure a high confidence 25 WO 2005/001114 PCT/GB2004/002739 level for the proposed peptide sequence. Moreover, if fragment ions representing the complete sequence of the peptide are present, the site of attachment of the phosphate group can be deduced from the position and 5 pattern of these fragment ions. Therefore, it is possible in most instances to discover the exact site of phosphorylation in each phosphopeptide. In scme instances we have even found MS/MS spectra to be heterogeneous. Here two (or more) distinct 10 phosphopeptides are represented in the same spectrum. This is because each phosphopeptide form has the same molecule weight and the same number of phosphate groups, but these are attached to different amino acids within the peptide. Therefore, both forms give rise to 15 precursor ions of the same m/z ratio, which are then selected simultaneously by the mass spectrometer during the MS/MS experiment. In such cases, we refer to the phosphopeptides concerned as "regiomers" 20 Multiplex Assays for Screening Compounds In drug development it is desirable to develop rapid high throughput assays with simple read out to show whether a compound has an effect on the proposed target. In the case of compounds inhibiting an enzyme function, such as 25 a kinase, it is possible to develop an artificial substrate for the target enzyme that is modified by the enzyme in a way that the level of modification can be readily detected. In the presence of an inhibitory compound, the substrate is not modified and this can also 30 be readily detected. In the case of inhibitors of tau phosphorylation, it is necessary to monitor the effect of inhibiting specific protein kinases on the phosphorylation status of a large 26 WO 2005/001114 PCT/GB2004/002739 number of sites. In one aspect, it is possible to prepare artificial substrates corresponding to each of the phosphorylation sites on tau and assess each compound for their ability to inhibit the phosphorylation of each 5 site independent of the other sites. In such a systeMn, each compound would be added to multiple wells each well containing the proposed kinase target, one of the phosphorylation site-specific artificial substrates and a reporter system to show phosphorylation, such as a .0 monoclonal antibody that binds specifically to the substrate in either the phosphorylated or unphosphorylated form, and which antibody is labelled with a fluorescent marker, an enzyme that converts a colour less substrate into a coloured product, or an .5 enzyme that promotes the production of a luminescent signal. In such an assay, it is desirable that the artificial substrate for the target is immobilised on a solid surface such that as part of the assay procedure any unreacted antibody is removed from the system by !0 washing before the result is read. Such assays may be run in microtitre wells of varying formats of typically 96, or more typically 384, or even more typically 153G wells, or alternatively may be run on a microarray based on a solid support such as glass. 5 Alternatively, the effect of different kinase inhibitors on the global phosphorylation status of tau may be designed. In such an assay, full length recombinant tau protein carrying no phosphorylations, or one or more 0 desirable phosphorylations may be used as the substrate. Alternatively, a mixture of equal amounts of all of the artificial substrates representing single phosphorylation sites may be used. Each screening assay will determine the effect of compounds on the inhibition of one, two or 27 WO 2005/001114 PCT/GB2004/002739 more protein kirnases with known activitity fcor the phosphorylation of tau. As with the more simple assays described above substrate, target kinase and compound are added to a well of a microtitre plate and incubated with 5 appropriate buffers and other constituents that permit the phosphorylation of substrate in the absence of an inhibitory compound. The phosphorylation status of the substrate may then be determined using a mixture of antibodies or other molecules with specificity for .0 individual phosphorylation sites on tau, wherein such antibodies or other molecules are each labelled with a unique reporter such as a fluorescent dye or compounds with unique spectral properties in infra-red, visible or ultraviolet spectra. After removal of antibodies that .5 remain unbound to the phosphorylated substrate(s), levels of each specific reporter are determined using an appropriate reading device, and the levels of phosphorylation at each specific site in tau is revealed by comparison with a control where no kinase inhibitor 0 was added. In a preferred embodiment of such a multiplex screening assay, the substrate is dephosphorylated recombinant tau protein and the kinase is selected from CK1, CK2, GSK-3a, 5 GSK-3b, PKA, CDK5, ERKI/2, SAPKlg, SAPK2a, SAPK2b, SAPK3, SAPK4, stress activated protein kinase family kinases (SAPKs) such as p38MAPK and JNK, MARK family kinases such as 110K, cdc2, cdk2, PKC, PKN, TTK, PKB, DYRK, PK, CaMKII, PKD, Rho kinase, or a mixture of one of more these 30 kinases. Reporter systems are preferably labelled antibodies, typically monoclonal antibodies, for example those that can be obtained from rabbits or mice using techniques well known in the art. Labels are preferably fluorescent or colorimetric compounds that are covalently 28 WO2005/001114 PCT/GB2004/002739 attached to antibodies, more preferably fluorescent or colorimetric nanoparticles and are most preferably nanoparticles with unique Raman spectra. 5 Development of Mimetic Substances Other candidate inhibitor compounds may be based on modelling the 3-dimensional structure of a polypeptide or peptide fragment ard using rational drug design to provide potential inhibitor compounds with particular 10 molecular shape, size and charge characteristics. Once candidate substance have been found in the assays and screens according to the present invention, they rnay be used to design mimetic compounds for development as 15 drugs. The designing of mimetics to a known pharmaceutically active compound is a known approach to the development of pharmaceuticals based on a "lead" compound. This might be desirable where the active compound is difficult or expensive to synthesise or where 20 it is unsuitable fcr a particular method of administration, e.g. peptides are unsuitable active agents for oral compositions as they tend to be quickly degraded by proteases in the alimentary canal. Mimetic design, synthesis and testing is generally used to avoid 25 randomly screening large number of molecules for a target property. There are several steps commonly taken in the design of a mimetic from a compound having a given target property. 30 Firstly, the particular parts of the compound that are critical and/or important in determining the target property are determined. In the case of a peptide, this can be done by systematically varying the amino acid residues in the peptide, e.g. by substituting each 29 WO 2005/001114 PCT/GB2004/002739 residue in turn. These parts or residues constituting the active region of the compound are known as its "pharmacophore". 5 Once the pharmacophore has been found, its structure is modelled to according its physical properties, e.g. stereochemistry, bonding, size and/or change, using data from a range of sources, eg spectroscopic techniques, X ray diffraction data and NMR. Computational analysis, LO similarity mapping (which models the charge and/or volume of a pharmacophore, rather than the bonding between atoms) and other techniques can be used inrl this modelling process. L5 In a variant of this approach, the three-dimensional structure of the ligand and its binding partner are modelled. This can be especially useful where the ligand and/or binding partner change conformation on binding, allowing the model to take account of this in the design 20 of the mimetic. A template molecule is then selected onto which chemical groups which mimic the pharmacophore can be grafted. The template molecule and the chemical groups grafted on to 25 it can conveniently be selected so that the mimetic is easy to synthesise, is likely to be pharmacologically acceptable, and does not degrade in vivo, while retaining the biological activity of the lead compound. The mimetic or mrnimetics found by this approach can then be 30 screened to see whether they have the target property, or to what extent they exhibit it. Further optimisation or modification can then be carried out to arrive at one or more final rnimetics for in vivo or clinical testing. 30 WO2005/001114 PCT/GB2004/002739 Pharmaceutical Compositions Following identification of a substance which modulates or affects phoEphorylation or dephosphorylation of taui protein, the substance may be investigated further. 5 Furthermore, it may be manufactured and/or used in preparation, i.e. manufacture or formulation, of a composition such as a medicament, pharmaceutical composition or drug. These may be administered to individuals LO Thus, the pr-esent invention extends in various aspects not only to a substance identified using the screening assays and assay methods disclosed herein, but also a pharmaceutical composition, medicament, drug or other 5 composition comprising such a substance, a method comprising administration of such a composition to a patient, e.g. to treat tauopathies, use of such a substance in manufacture of a composition for administration for the treatment of tauopathies, arid a 10 method of making a pharmaceutical composition comprising admixing such a substance with a pharmaceutically acceptable excipient, vehicle or carrier, and optionally other ingredients. :5 The substances identified as kinase inhibitors or phosphatase promoters in the assays and assay methods of the present invention, or compounds or substances arising from further development or optimisation, may be formulated in pharmaceutical compositions. These 0 compositions may be employed for the treatment of tauopathies, that is conditions which are characterised by neurofibrillary tangles or aggregates of tau protein. Tauopathies are a recognised class of conditions known to those skilled in the art and include Alzheimer's diLsease, 31 WO 2005/001114 PCT/GB2004/002739 frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclea.r palsy (PSP), Pick's disease, corticobasal degeneration, multisystem atrophy (MSA), neurobasal degeneration with 5 iron accumulation, type 1 (Hallervorden-Spatz), argyrophilic grain dementia, Down's syndrome, diffuse neurofibrillary tangles with calcification, dementia pugilistica, Gerstmann-Striussler-Scheinker disease, myotonic dystrophy, Niemann-Pick disease type C, 10 progressive subcortical gliosis, prion protein cerebral amyloid angiopathy, tangle only dementia, postenacephalitic parkinsonism, subacute sclerosing panencephalitis, Creutzfeldt-Jakob disease, amyotrophic lateral sclerosis/parkinsonism-dementia complex, non-Guamanian 15 motor neuron disease with neurofibrillary tangles/dementia, and Parkinson's disease. The intracellular tau deposits are usually neuronal or glial and are filamentous and generally in a hyperphosphorylated state as compared to the level of phosphorylation in tau 20 from control human brain. In the case of AD, this hyperphosphorylated tau is often referred to a paired helical filament tau (PHF) tau because it is derived from the PHF. 25 These compositions may comprise, in addition to one of the above substances, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of 30 the active ingredient. The precise nature of the carrier or other material may depend on the route of administration, e.g. oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal routes. 32 WO 2005/001114 PCT/GB2004/002739 Pharmaceutical compositions for oral administration may be in tablet, capsule, powder or liquid form. A tablet may include a solid carrier such as gelatin or an adjuvant. 5 Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, 10 propylene glycol or polyethylene glycol may be included. For intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous 15 solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's 20 Injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required. Whether it is a polypeptide, antibody, peptide, nucleic 25 acid molecule, small molecule or other pharmaceutically useful compound according to the present invention that is to be given to an individual, administration is preferably in a "prophylactically effective amount" or a "therapeutically effective amount" (as the case may be, 30 although prophylaxis may be considered therapy) , this being sufficient to show benefit to the individual. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. 33 WO 2005/001114 PCT/GB2004/002739 decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors, andc typically takes account of the disorder to be treated, the condition of the individual patient, the site off 5 delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in Remingtonr s Pharmaceutical Sciences, 20th Edition, 2000, pub. Lippincott, Williams & Wilkins. A composition may be 10 administered alone or in combination with other treatments, either simultaneously or sequentially, dependent upon the condition to be treated. Materials and Methods 15 Mass Spectrometry Data Acquisition Following SDS-PAGE the gel bands relating to PHF-taa were excised, reduced, alkylated and digested with trypsin. Peptides were extracted from the gel pieces by a series 20 of acetonitrile and aqueous washes. The extract was pooled with the initial supernatant and lyophilised. Each sample was then resuspended in 6 ml of 50mM ammonium bicarbonate and analysed by LC/MS/MS. Chromatographic separations were performed using an Ultimate LC system 25 (Dionex, UK). Peptides were resolved by reverse phase chromatography on a 75 mm C18 PepMap column. A gradient of acetonitrile in 0.05% formic acid was delivered to elute the peptides at a flow rate of 200 nl/min. Peptides were ionised by electrospray ionisation using a 30 Z-spray source fitted to a Q-Tofmicro (Micromass, U<). The instrument was set to run in automated switching mode, selecting precursor ions based on their intensity, for sequencing by collision-induced fragmentation. 34 WO 2005/001114 PCT/GB2004/002739 Data Analysis The mass spectral data was processed into peak lists and searched against the full-length sequence of Tau-6 (441 amino acids; mw 45847) using Mascot software (Matrix 5 Science, UK). Phosphorylated peptides were identified by selecting phosphate as a variable modification within the searching parameters. Serine, threonine and tyrosine phosphorylation were all considered. The exact location of the modification within each peptide was determined by 10 the pattern of fragment ions produced (see below for further explanation). Tandem Mass Spectrometry To obtain definitive evidence and determine the exact 15 site of phosphorylation, peptides were separated by reversed-phase chromatography and sequenced by tandem MS/MS. In these experiments precursor ions relating to each of the phosphopeptides are individually selected and subjected to collision induced dissociation (CID). 20 Fragment ions so produced are indicative of the sequence of the phosphopeptide and the site of modification is determined by the molecular weight of the relevant fragment ions. Conversely, other potential sites of phosphorylation within particular phosphopeptides can 25 also be ruled out by the presence of other fragment ions within the MS/MS spectrum. An unexpected observation is that on some occasions it has been possible to pinpoint several discrete forms of 30 phosphopeptides within a single MS/MS spectrum. Here the phosphopeptides each have the same molecular weight (and so are selected simultaneously), but differ in the site(s) of phosphorylation. Thus, the fragment ions observed are effectively a composite representation of 35 WO 2005/001114 PCT/GB2004/002739 each molecule being analysed. Purification of PHF-tau from Alzheimer brain Paired helical filament (PHF) tau was purified from 5 Alzheimer brain as described in (Hanger et al, 1998). Briefly, brain tissue was homogenised and insoluble PHF tau was recovered by differential centrifugation. Following solubilisation in guanidine and dialysis against a re-naturing buffer, PHF-tau was purified by 10 anion-exchange and reversed-phase chromatography. Preparation and purification of recombinant human tau A plasmid expressing the largest tau isoform (2N4R) was used to prepare and purify recombinant human tau as 15 described previously (Mulot et al, 1994). Briefly, a bacterial cell lysate expressing 2N4R tau was heated and centrifuged to remove heat-labile proteins. The supernatant was fractionated with ammonium sulphate and precipitated material was solubilised and dialysed into 20 buffer prior to cation-exchange chromatography. Proteins were eluted with NaCl and fractions containing tau were pooled and dialysed against ammonium bicarbonate before lyophilisation. 25 In vitro phosphorylation of recombinant tau by serine /threonine protein kinases Recombinant human tau (40pg/ml) was incubated with 67U/ml casein kinase 1 (CK1), 67U/ml casein kinase 2 (CK2), 167U/ml cyclic AMP-dependent protein kinase (PKA), 67U/ml 30 glycogen synthase-3p (GSK-33) or all four kinases in combination, each at the stated concentration, in the presence of 3mM ATP for 6h at 30 0 C. Each kinase was obtained in a purified recombinant form from New England Biolabs. 36 WO 2005/001114 PCT/GB2004/002739 In-gel proteolytic digestion of tau PHF-tau or in vitro phosphorylated tau proteins were separated on 10 % (wt/vol) polyacrylamide gels and 5 stained with colloidal Coomassie Blue G. Protein bands corresponding to tau were excised, carbamidomethylated, and digested with proteolytic enzymes (trypsin or Asp-N) Peptides were extracted from gel pieces by a series of acetonitrile and aqueous washes, dried and resuspended in 10 50mM ammonium bicarbonate. Amyloid beta treatment of neurons Rat and human cortical neurons were treated with AP peptide (25-35) or reverse AP peptide (35-25) for 1-10 15 min. Proteins containing phosphotyrosine were immunoprecipitated and separated by SDS-PAGE. Western blots of heat-stable extracts of neuronal cultures and immunoprecipitates were probed with antibodies to tau. 20 Results New sites found in PHF-tau Current literature reports 25 known phosphorylation sites (all are serine or threonine) identified by direct means in PHF-tau (Hanger et al, 1998). There are a further 2-3 25 sites that have been identified by antibody reactivity only. We have found an additional 12 phosphorylation sites in PHF-tau, one of which is a tyrosine residue (tyr394), bringing the total number of sites to 37. Four of the new sites are more amino terminal in tau than any 30 previously reported sites and three sites are more carboxy terminal than found previously. Of the 12 new sites, 4 are present in alternatively-spliced regions of tau and therefore are present only in specific tau isoforms, all previously identified PHF-tau 37 WO 2005/001114 PCT/GB2004/002739 phosphorylation sites are present in all tau isoforms. Only one of the 12 new sites in PHF-tau (either thr414 or ser416) is detected in tau from normal brain (ser416) 5 New sites on recombinant tau for each of the 4 serine/threonine kinases investigated See also Table 1 CKI found 28 new sites making a total of 30 sites 10 in all. 17 CK1 sites are present in PHF-tau, including 15 of the new CK1 sites. CK1 is a candidate kinase for 6 of the 12 new PHF-tau sites. 15 CK2 found 5 new sites making a total of 8 in all. 5 CK2 sites are present in PHF-tau, including 3 of the new CK2 sites. CK2 is a candidate kinase for 3 of the 12 new PHF-tau sites 20 GSK-3 found 12 new sites making a total of 38 in all. 21 GSK-3 sites are present in PHF-tau, including 5 of the new GSK-3P sites. GSK-3 is a candidate kinase for 4 of the 12 new PHF-tau sites 25 PKA found 5 new sites making a total of 24 in all. 16 PKA sites are present in PHF-tau, including 4 of the new PKA sites. PKA is a candidate kinase for 2 of the 12 new PHF-tau sites 30 Comparing PHF-tau phosphorylation sites with the recombinant tau and kinase data, when all of the phosphorylation sites for CK1, GSK-3, and PKA are combined, 30-33 of the 37 PHF-tau sites are phosphorylated (3 sites are defined only as one of two 38 WO 2005/001114 PCT/GB2004/002739 adjacent residues) Of the residual 4 to 7 sites, one is a tyrosine residue that requires tyrosine kinase activity, 4 other sites have no known kinase and the remaining 2 sites are each contained within regions where 5 only 1 of 2 nearby residues are phosphorylated (T11i and S185). Seven of the 12 new phosphorylation sites in PHF-tau could be generated by CK1, GSK-3, or PKA, four have no 10 known kinase and the fifth site required a tyrosine kinase for phosphorylation. Combining the four kinases together in a single reaction, we generated one site (thr111) that was not detected with 15 any of the four kinases alone, this residue is not phosphorylated by any other known kinase in vitro. Phosphorylation at this residue is also present in PHF tau. These results show that combinations of kinases can result in phosphorylation at new sites, possibly due to 20 conformational changes induced by the primary phosphorylation step that increase the likelihood of the secondary phosphorylation, possibly by a second enzyme . Amyloid beta treatment of neurons 25 We found that treatment of neurons with AP peptide increased tyrosine phosphorylation of neuronal proteins including tau. The increase in phosphotyrosine induced by AP was approximately four times the basal level in tau. 30 Future experiments Identify phosphorylation sites of other individual and combinations of protein kinases to emulate PHF-tau phosphorylation in vitro. Kinases that have been 39 WO2005/001114 PCT/GB2004/002739 implicated in tauopathies include GSKL3a, ERKs 1 & 2, cdk5, cdc2 kinase, JNK, several members of the SAP kinase family (ly, 2a, 2b, 3, 4), p38MAP kinase, calmodulin dependent kinase, PKC, MARK, PKN, PKB, TTK, DYRK, Rho 5 kinase and phosphorylase kinase. Determine if phosphorylation of tau with these kinases and other tyrosine kinases induces tau aggregation in vitro and in cells. This will allow us to identify the 10 phosphorylation sites that are critical for tau aggregation. Investigate the effects of specific protein kinase inhibitors, alone and in combination, on tau aggregation 15 in an in vitro or cellular context. Generate transgenic mice (inducibly) expressing CK1 and determine if this model shows cerebral tau deposition. Cross this mouse with other mice expressing candidate 20 kinases (eg a GSK-3 mouse already exists) and examine the rate of tangle formation. We have recently found (unpublished) that tyr394 is phosphorylated in AD and in foetal tau and have reported 25 that this same residue is phosphorylated by both Fyn and Lck in vitro. Fyn has been shown previously to phosphorylate tau and Fyn is increased in a sub-set of neurons in AD. It is also known that AP treatment of neurons induces tau phosphorylation and that Fyn knock 30 out mice are resistant to AI. 40 WO 2005/001114 PCT/GB2004/002739 We will treat neurons from wild-type, Fyn knock-out and Src knock-out mice with AP and identify the phosphorylation sites on tau in each case. 5 It is possible that other tyrosine kinases are involved in tau phosphorylation and aggregation and these include those associated with growth factor and neurotrophic factor receptors. Other tyrosine kinase families may also be involved, including Syk kinase, which has been 10 show to phosphorylate another protein (c-synuclein) implicated in neurodegenerative disease in a manner that increases its propensity to aggregate in vitro. In each case, we will investigate the effects of phosphorylation on tau aggregation and the effects of kinase inhibition 15 on tau aggregation. 20 41 WO 2005/001114 PCT/GB2004/002739 Table 1: New sites identified in tau as phosphorylated by individual serine/threonine kinases Kinase New sites identified New sites Kinase sites in recombinant tau present in PHF- present in 12 tau new PHF-tau sites CKI (46/50), 113, 131, 113, 184, 208, (111/113) , 149, 169, 184, 208, (210, 212), 214, 258, 289, (210, 212) , 214, 237, 238, 258, 416, 433, 435 237, 238, 241, 258, 262, 289, 356, (412/413/414/ 262, 263, 285, 289, (412/413/414/416 416, 2 sites) 305, 341, 352, 356, , 2 sites), 416, 361, 373, 386, 433, 435 (412/413/414/416, 2 sites), 416, 433, 435 CK2 (52/56), 199, 386, 199, 400, (412/413/414/ 400, (412/413/414/416 416, 1 site) (412/413/414/416, 1 , 1 site) site) GSK-3 149, 220, 237, 241, 237, 258,.289, 258, 289, 245, 258, 285, 289, (409/412/413/414 (409/412/413/ 305, 352, 373, /416, 2 sites of 414/416, 2 (409/412/413/414/416 which 1 or 2 are sites of , 2 sites of which 1 new) which 1 cr 2 or 2 are new) are new) 69 (this site is already known for GSK, but is new in PHF tau) PKA 210, (217/220), 258, 210, (217/220), 258, 416 352, (412/413) 258, (412/413) The 12 new sites in PHF-tau are: 5 68, 69, 71, (111/113), 191, 258, 289, Y394, (414/416) 427, 433, 435 .0 42 WO 2005/001114 PCT/GB2004/002739 Table 2 Q) T17 T17 Y18 Y18 Y29 Y29 T30 T30 T39 *T39 S46 A * r 46 T50 N * T50 T52 ET52 856 SN 56 861. S61 S64 S64 S68 * 6 T69 *-*. T69 T71 *T71 T76 T76 T95 T95 T101 T101 T102 T102 T111l T111 S113 6 N S113 T123 T123 S129 S12 9 S131 *NS131 T13 5 T13 5 S137 S137 T14 9 N*NT14 9 T153 A *.T153 T16 9 NT16 9 T175 * * 17 -5 T181 **T181 S184 S 184 S185 S185 S191 * 191 8195 * 195 Y197 Y197 S198 * 198 S199 * N * 19 S202 *202 T205. T205 S208 **N (* S208 S210_, 17 6i 1 S2 10 T212 *N*T212 S214 *SN 214 T217 **T217 T220 *NT220 T231 **T231 S235 *S 235 S237 *SN* 237 S238 *238 S241 *24 T245 *N T2 45| 43 WO 2005/001114 PCT/GB2004/002739 S258 * *N *N *N s258 S262 * * * 262 T263 *N T263 A = identified by antibody labelling, etc =one of two adjacent sites phosphorylated in PHF-tau; suspected sites in PHF-tau New PHF-tau sites indicated in red italics. 285Kinase phosphorylation sites*N 285 Shaded sites indicate multiple (numbered) phosphorylations at less S289well-defined sites, N indicates a new site.289 Some of the kinase phosphorylation sites were identified a-sing antibodies 10 Kinase sites identified by MS or antibodies are all compiled together in this table (*) =GSK is phosphorylated on these sites after priming ath other sites 44 S293_ * S293 S3 05 *N *N S 305 Y310 Y310 S316 S316 T319 T319 S320 S 320 S324 *S324 S341 *NS341 S352 *N*N IT S352 S356 **N * * S356 T361 *N T361 T373 *N *N T373 T377- - ', T377 T386 *N *N T386 Y394 *Y394 S396 * 396 S400 **N *S400 T403 *()T03 S404 *S 404 S409 * S 409 S412 * N tN NS 41.2 S413 *N "N NS 413 T414 6N N N T414 S416 ^'N "N N S41 6 S422 *S422 T427 *T427 S433 *Nq S433 S435 *NT S435 *=identified phosphorylation site A =identified by antibody labelling; 1- etc =one of two adjacent sites phosphorylated in PHF-tau; = suspected sites in PHPF-tau New PHF-tau sites indicated in red italics. 5 Kinase p tosphorylation sites Shaded asLtes indicate multiple (numbered) pho sphoryl at ions at less well-defined sites, N indicates a new site. Some of the kinase phosphorylation sites were identified using antibodies 10 Kinase siLtes identified by MS or antibodies are all compiled together in this table (*) = GSK is phosphorylated on these sites after priming a-t other sites 44 WO 2005/001114 PCT/GB20041002739 Table 3 Vi 0m T69 T* T71. '171 7T175 T7 T181 T11 S18~4 0 *81 S185 S18 S191 S19* 0208 320 S2'10 *21 T212 ** * T2l12 S214 ' *** S211 T231 *21: -S235 S-3 :S237 * N23 S238 * S3 S258 *N S2TG2 *I*S6 S289 *NS8 S356~ NS5 Y394 7 *'34 S39G *39 7403 T40 S4 C4 A.__40 S409 *40 T44 <L7 * N* T41 S416 S415 ~ 0422 *42 T427 14 7 B433 S43 45 WO 2005/001114 PCT/GB2004/002739 References The references mentioned herein are all expressly incorporated by reference. 5 Ghoshal N, Smiley JF, DeMaggio AJ, Hoekstra MF, Cochran EJ, Binder LI, Kuret J. (1999) A new molecular link between the fibrillar and granulovacuolar lesions of Alzheimer's disease. Am J Pathol. 155, 1163-72. 10 Hanger DP, Betts JC, Loviny TL, Blackstock WP, Anderton BH. (1998) New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J Neurochem. 71, 2465-76. 15 Lambert,M.P., Barlow,A.K., Chromy,B.A., Edwards,C., Freed,R., Liosatos,M., Morgan,T.E., Rozo-vsky,I., Trommer,B., Viola,K.L., Wals,P., Zhang,C., Finch,C.E., Krafft,G.A., and Klein,W.L. (1998). Diffusible, 20 nonfibrillar ligands derived from AI-.
42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 95, 6448-6453. Lee VM, Goedert M, Trojanowski JQ. (2001) 25 Neurodegenerative tauopathies. Annu Rev INeurosci. 24, 1121-59. Mulot SF, Hughes K, Woodgett JR, Anderton BH, Hanger DP. (1994) PHF-tau from Alzheimer's brain comprises four 30 species on SDS-PAGE which can be mimicked by in vitro phosphorylation of human brain tau by glycogen synthase kinase-3 beta. FEBS Lett. 349, 359-64. 46 WO 2005/001114 PCT/GB2004/002739 Scales,TME, Williamson, R., Anderton, BH, Renolds, CH et al (2002) Tyrosine phosphorylation of specific sites on tau by Src family kinases. Neurobiol Aging 23, S500-501. 5 Shirazi,S.K. and Wood,J.G. (1993). The protein tyrosine kinase, fyn, in Alzheimer's disease pathology. Neuroreport 4, 435-437. Singh TJ, Zaidi T, Grundke-Iqbal I, Iqbal K. (1995a) 10 Modulation of GSK-3-catalyzed phosphorylation of microtubule-associated protein tau by non-proline dependent protein kinases. FEBS Lett. 358, 4-8. Singh TJ, Haque N, Grundke-Iqbal I, Iqbal K. (1995b) 15 Rapid Alzheimer-like phosphorylation of tau by the synergistic actions of non-proline-dependent protein kinases and GSK-3. FEBS Lett. 358, 267-72. Williamson,R., Scales,T., Clark,B.R., Gibb,G., 20 Reynolds,C.H., Kellie,S., Bird,I.N., Varndell,I.M., Sheppard,P.W., Everall,I., and Anderton,B.H. (2002). Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-P peptide exposure: involvement of Src family 25 protein kinases. J. Neurosci. 22, 10-20. 47 WO 2005/001114 PCT/GB2004/002739 SEQUENCE LISTING <110> Proteome Science plc Kings College London 5 Anderton, Brian Hanger, Diane Ward, Malcolm Byers, Helen .0 <120> Screening Methods <130> SJK/BP6234025 <150> GB 0314943.2 .5 <151> 2003-06-25 <160> 3 <170> PatentIn version 3.1 !0 <210> 1 <211> 428 <212> PRT <213> Rattus norvegicus .5 <400> 1 Met Glu Leu Arg Val Gly Asn Arg Tyr Arg Leu Gly Arg Lys Ile Gly 1 5 10 15 10 Ser Gly Ser Phe Gly Asp Ile Tyr Leu Gly Thr Asp Ile Ala Ala Gly 20 25 30 5 Glu Glu Val Ala Ile Lys Leu Glu Cys Val Lys Thr Lys His Pro Gln 35 40 45 10 Leu His Ile Glu Ser Lys Ile Tyr Lys Met Met Gln Gly Gly Val Gly 50 55 60 Ile Pro Thr Ile Arg Trp Cys Gly Ala Glu Gly Asp Tyr Asn Val Met [5 65 70 75 80 Val Met Glu Leu Leu Gly Pro Ser Leu Glu Asp Leu Phe Asn Phe Cys 85 90 95 50 Ser Arg Lys Phe Ser Leu Lys Thr Val Leu Leu Leu Ala Asp Gln Met 100 105 110 55 Ile Ser Arg Ile Glu Tyr Ile His Ser Lys Asn Phe Ile His Arg Asp 115 120 125 50 Val Lys Pro Asp Asn Phe Leu Met Gly Leu Gly Lys Lys Gly Asn Leu 130 135 140 48 WO 2005/001114 PCT/GB2004/002739 Val Tyr Ile Ile Asp Phe Gly Leu Ala Lys Lys Tyr Arg Asp Ala Arg 145 150 155 160 5 Thr His Gln His Ile Pro Tyr Arg Glu Asn Lys Asn Leu Thr Gly Thr 165 170 175 0 Ala Arg Tyr Ala Ser- Ile Asn Thr His Leu Gly Ile Glu Gln Ser Arg 180 185 190 Arg Asp Asp Leu GluL Ser Leu Gly Tyr Val Leu Met Tyr Phe Asn Leu 5 195 200 205 Gly Ser Leu Pro Trp Gln Gly Leu Lys Ala Ala Thr Lys Arg GKIn Lys 210 215 220 0 Tyr Glu Arg Ile Ser Glu Lys Lys Met Ser Thr Pro Ile Glu Val Leu 225 230 235 240 5 Cys Lys Gly Tyr Pro Ser Glu Phe Ala Thr Tyr Leu Asn Phe Cys Arg 245 250 255 0 Ser Leu Arg Phe Asp Asp Lys Pro Asp Tyr Ser Tyr Leu Arg GIn Leu 260 265 270 Phe Arg Asn Leu Phe His Arg Gln Gly Phe Ser Tyr Asp Tyr Val Phe ;5 275 280 285 Asp Trp Asn Met Leu Lys Phe Gly Ala Ser Arg Ala Ala Asp Asp Ala 290 295 300 :0 Glu Arg Glu Arg Arg Asp Arg Glu Glu Arg Leu Arg His Ser Arg Asn 305 310 315 320 -5 Pro Ala Thr Arg Gly Leu Pro Ser Thr Ala Ser Gly Arg Leu A2rg Gly 325 330 335 -0 Thr Gln Glu Val Ala Pro Pro Thr Pro Leu Thr Pro Thr Ser Elis Thr 340 345 350 Ala Asn Thr Ser Pro Arg Pro Val Ser Gly Met Glu Arg Glu Arg Lys 35 355 360 365 Val Ser Met Arg Leu His Arg Gly Ala Pro Val Asn Val Ser Ser Ser 370 375 380 30 49 WO 2005/001114 PCT/GB2004/002739 Asp Leu Thr Gly Arg Gln Asp Thr Ser Arg Met Ser Thr Ser Gln Arg 385 390 395 400 5 Ser Arg Asp Met Ala Ser Leu Arg Leu His Ala Ala Arg Gln Gly Ala 405 410 415 Arg Cys Arg Pro Gln Arg Pro Arg Arg Thr Thr Tyr 0 420 425 <210> 2 <211> 441 5 <212> PRT <213> Homo sapiens <400> 2 Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly 0 1 5 10 15 Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His 20 25 30 5 Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu 35 40 45 0 Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser 50 55 60 5 Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val 65 70 75 80 Asp Glia Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu 0 85 90 95 Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro 100 105 110 :5 Ser Le-u Glu Asp Glu Ala Ala Gly His Val Thr Gln Ala Arg Met Val 115 120 125 0 Ser Lys Ser Lys Asp Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Gly 130 135 140 5 Ala Asp Gly Lys Thr Lys Ile Ala Thr Pro Arg Gly Ala Ala Pro Pro 145 150 155 160 Gly Glri Lys Gly Gln Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro 0 165 170 175 50 WO 2005/001114 PCT/GB2004/002739 Pro Ala Pro Lys Thr Pro Pro Ser Ser Gly Glu Pro Pro Lys Ser Gly 180 185 190 5 Asp Arg Ser Gly Tyr Ser Ser Pro Gly Ser Pro Gly Thr Pro Gly Ser 195 200 205 10 Arg Ser Arg Thr Pro Ser Leu Pro Thr Pro Pro Thr Arg Glu Pro Lys 210 215 220 Lys Val Ala Val Val Arg Thr Pro Pro Lys Ser Pro Ser Ser Ala Lys 15 225 230 235 240 Ser Arg Leu Gln Thr Ala Pro Val Pro Met Pro Asp Leu Lys Asn Val 245 250 255 20 Lys Ser Lys Ile Gly Ser Thr Glu Asn Leu Lys His Gln Pro Gly Gly 260 265 270 25 Gly Lys Val Gln Ile Ile Asn Lys Lys Leu Asp Leu Ser Asn Val Gln 275 280 285 Ser Lys Cys Gly Ser Lys Asp Asn Ile Lys His Val Pro Gly Gly Gly 30 290 295 300 Ser Val Gln Ile Val Tyr Lys Pro Val Asp Leu Ser Lys Val Thr Ser 305 310 315 320 35 Lys Cys Gly Ser Leu Gly Asn Ile His His Eys Pro Gly Gly Gly Gln 325 330 335 40 Val Glu Val Lys Ser Glu Lys Leu Asp Phe Lys Asp Arg Val Gln Ser 340 345 350 45 Lys Ile Gly Ser Leu Asp Asn Ile Thr His Val Pro Gly Gly Gly Asn 355 360 365 Lys Lys Ile Glu Thr His Lys Leu Thr Phe Arg Glu Asn Ala Lys Ala 50 370 375 380 Lys Thr Asp His Gly Ala Glu Ile Val Tyr Lys Ser Pro Val Val Ser 385 390 395 400 55 Gly Asp Thr Ser Pro Arg His Leu Ser Asn Val Ser Ser Thr Gly Ser 405 410 415 6O Ile Asp Met Val Asp Ser Pro Gln Leu Ala Thr Leu Ala Asp Glu Val 51 WO 2005/001114 PCT/GB2004/002739 420 425 430 Ser Ala Ser Leu Ala Lys Gln Gly Leu 5 435 440 <210> 3 <211> 537 .0 <212> PRT <213> Homo sapiens <400> 3 .5 Met Gly Cys Val Gln Cys Lys Asp Lys Glu Ala Thr Lys Leu Thr GLU 1 5 10 15 Glu Arg Asp Gly Ser Leu Asn Gln Ser Ser Gly Tyr Arg Tyr Gly Thr 0 20 25 30 Asp Pro Thr Pro Gln His Tyr Pro Ser Phe Gly Val Thr Ser Ile Pro 35 40 45 Asn Tyr Asn Asn Phe His Ala Ala Gly Gly Gln Gly Leu Thr Val Phle 50 55 60 10 Gly Gly Val Asn Ser Ser Ser His Thr Gly Thr Leu Arg Thr Arg Gly 65 70 75 80 Gly Thr Gly Val Thr Leu Phe Val Ala Leu Tyr Asp Tyr Glu Ala Ar-g 15 85 90 95 Tlhr Glu Asp Asp Leu Ser Phe His Lys Gly Glu Lys Phe Gln Ile Leu 100 105 110 t0 Asn Ser Ser Glu Gly Asp Trp Trp Glu Ala Arg Ser Leu Thr Thr GLy 115 120 125 15 Giu Thr Gly Tyr Ile Pro Ser Asn Tyr Val Ala Pro Val Asp Ser ILe 130 135 140 50 Gln Ala Glu Glu Trp Tyr Phe Gly Lys Leu Gly Arg Lys Asp Ala GLu 145 150 155 160 A rg Gln Leu Leu Ser Phe Gly Asn Pro Arg Gly Thr Phe Leu Ile Arg 55 165 170 175 Glu Ser Glu Thr Thr Lys Gly Ala Tyr Ser Leu Ser Ile Arg Asp Trp 180 185 190 50 52 WO 2005/001114 PCT/GB2004/002739 Asp Asp Met Lys Gly Asp His Val Lys His Tyr Lys Ile Arg Lys Leu 195 200 205 5 Asp Asn Gly Gly Tyr Tyr Ile Thr Thr Arg Ala Gln Phe Glu Thr Leu 210 215 220 Gln Gln Leu -Val Gln His Tyr Ser Glu Arg Ala Ala Gly Leu Cys Cys .0 225 230 235 240 Arg Leu Val Val Pro Cys His Lys Gly Met Pro Arg Leu Thr Asp Leu 245 250 255 .5 Ser Val Lys Thr Lys Asp Val Trp Glu Ile Pro Arg Glu Ser Leu Gln 260 265 270 :0 Leu Ile Lys Arg Leu Gly Asn Gly Gln Phe Gly Glu Val Trp Met Gly 275 280 285 5 Thr Trp Asn Gly Asn Thr Lys Val Ala Ile Lys Thr Leu Lys Pro Gly 290 295 300 Thr Met Ser Pro Glu Ser Phe Leu Glu Glu Ala Gln Ile Met Lys Lys 0 305 310 315 320 Leu Lys His Asp Lys Leu Val Gln Leu Tyr Ala Val Val Ser Glu Glu 325 330 335 '5 Pro Ile Tyr Ile Val Thr Glu Tyr Met Asn Lys Gly Ser Leu Leu Asp 340 345 350 ;0 Phe Leu Lys Asp Gly Glu Gly Arg Ala Leu Lys Leu Pro Asn Leu Val 355 360 365 :5 Asp Met Ala Ala Gln Val Ala Ala Gly Met Ala Tyr Ile Glu Arg Met 370 375 380 Asn Tyr Ile His Arg Asp Leu Arg Ser Ala Asn Ile Leu Val Gly Asn 0 385 390 395 400 Gly Leu Ile Cys Lys Ile Ala Asp Phe Gly Leu Ala Arg Leu Ile Glu 405 410 415 5 Asp Asn Glu Tyr Thr Ala Arg Gln Gly Ala Lys Phe Pro Ile Lys Trp 420 425 430 .0 Thr Ala Pro Glu Ala Ala Leu Tyr Gly Arg Phe Thr Ile Lys Ser Asp 53 WO 2005/001114 PCT/GB2004/002739 435 440 445 Val Trp Ser Phe Gly Ile Leu Leu Thr Glu Leu Val Thr Lys Gly Arg 5 450 455 460 Val Pro Tyr Pro Gly Met Asn Asn Arg Glu Val Leu Glu Gln Val Glu 465 470 475 480 10 Arg Gly Tyr Arg Met Pro Cys Pro Gln Asp Cys Pro Ile Ser Leu His 485 490 495 L5 GlLu Leu Met Ile His Cys Trp Lys Lys Asp Pro Glu Glu Arg Pro Thr 500 505 510 20 Phe Glu Tyr Leu Gln Ser Phe Leu Glu Asp Tyr Phe Thr Ala Thr Glu 515 520 525 Pro Gln Tyr Gln Pro Gly Glu Asn Leu 25 530 535 54

权利要求:
Claims (50)
[1] 1. Use of casein kinase 1, or a nucleic acid molecule encoding the casein kinase 1, for screening for candidate compounds which are capable of (a) inhibiting the 5 activity of casein kinase 1 in phosphorylating a tau protein or (b) binding to casein kinase 1 to inhibit its interaction with a tau protein.
[2] 2. The use of claim 1, wherein the casein kinase 1 is a 10 fragment or derivative of full length casein kinase 1 having the amino acid sequence set out between amino acids 1 and 428 inclusive in SEQ ID NO: 1.
[3] 3. The use of claim 1 or claim 2, wherein the casein 15 kinase 1 has greater than 80% sequence identity with full length casein kinase 1 having the amino acid sequence set out between amino acids 1 and 428 inclusive of SEQ ID NO: 1. 20
[4] 4. The use of claim 1 or claim 2, wherein the nucleic acid molecule encoding the casein kinase 1 is capable of hybridising under stringent conditions to a nucleic acid molecule encoding full Length casein kinase 1 having the amino acid sequence set out in SEQ ID NO: 1. 25
[5] 5. The use of any one of the preceding claims, wherein the tau protein is paired helical filament tau.
[6] 6. The use of any one of claims 1 to 4, wherein the tau 30 protein is a fragment or- derivative of full length tau protein having the amino acid sequence set out between amino acids 1 and 441 inclusive in SEQ ID NO: 2.
[7] 7. The use of any one of the preceding claims, wherein 55 WO 2005/001114 PCT/GB2004/002739 the tau protein has greater than 80% sequence identity with full tau protein having the amino acid sequence set out between amino acids 1 and 441 inclusive in SEQ ID NO: 2. 5
[8] 8. The use of any one of claims 1 to 5, wherein a nucleic acid molecule encoding the tau protein is capable of hybridising under stringent conditions to a nucleic acid molecule encoding full length tau protein having the 10 amino acid sequence set out in SEQ ID NO: 3.
[9] 9. The use of any one of the preceding claims, wherein the casein kinase 1 phosphorylates tau protein at one or more sites selected from the group consisting of 15 (S46/T50), S113, S131, T149, T169, S184, S208, (S210/T212), S214, S237, S238, S241, S258, S262, T263, S285, S289, S305, S341, S352, S356, T361, T373, T386, (S412/S413/T414), S416, S433 and S435 of tau protein. 20
[10] 10. The use of claim 9, wherein the sites of the tau protein are selected from S262 and/or S356.
[11] 11. The use of claim 9, wherein the sites of the tau protein at one or more sites selected from the group 25 consisting of S113, S258, S289, S416, S433 and S435.
[12] 12. The use of any one of the preceding claims, wherein the screening comprises determining the effect of contacting the candidate compound(s) with a combination 30 of kinases, simultaneously or sequentially applied toc the candidate compounds and casein kinase 1.
[13] 13. The use of claim 12, wherein the combination of kinases comprises casein kinase 1 (CK1) in combinaticn 56 WO 2005/001114 PCT/GB2004/002739 with one or more of casein kinase 2 (CK2), protein kiraase A (PKA), glycogen synthase kinase 3a (GSK-3a) or glycogen synthase kinase 3P (GSK-3) . 5
[14] 14. The use of claim 12, wherein the combination of kinases comprises casein kinase 1 (CK1) in combination with PKA and GSK-33.
[15] 15. The use of any one of the preceding claims, wherein 10 the screening comprises determining whether, and optionally the extent to which, the candidate compound inhibits the phosphorylation of a substrate by the casein kinase 1. 15
[16] 16. The use of claim 15, wherein the substrate of casein kinase 1 is not a tau protein or a fragment thereof.
[17] 17. The use of claim 15 or claim 16, wherein the screening further comprises confirming whether a 20 candidate compound selected in an initial screen has the property of inhibiting the phosphorylation of the tau protein under conditions in which the casein kinase 1 is capable of phosphorylating the site(s) of the tau protein in the absence of the candidate compound. 25
[18] 18. The use of any one of the preceding claims, wherein mass spectroscopy or a site specific recognition agent is used to determine the presence, absence or extent of phosphorylation at one or more sites of the tau proteLn. 30
[19] 19. The use of claim 18, wherein the site specific recognition agent is a monoclonal antibody. 57 WO 2005/001114 PCT/GB2004/002739
[20] 20. The use of any one of the preceding claims, wherein the screening is carried out irl a multiplex assay employing a solid phase on which a plurality of substrates are immobilised. 5
[21] 21. The use of claim 20, wherein the substrates correspond to phosphorylation sites of tau protein.
[22] 22. A method of screening for substances which are LO capable of inhibiting the phosphorylation of a tau protein by casein kinase 1 (CKl), wherein the tau protein comprises one or more phosphorylation sites, the method comprising: (a) contacting at least cne candidate substance, 15 the tau protein and casein kinase 1 under conditions in which the casein kinase 1 is capable of phosphorylating the site(s) of the tau protein in the absence of the candidate substance; (b) determining whether, and optionally the extent 20 to which, the candidate substance inhibits the phosphorylation of the tau protein at one or more sites of the tau protein by casein kinase 1; and, (c) selecting the candidate substance which inhibits phosphorylation of the tau protein at one or 25 more of the sites.
[23] 23. The method of claim 22, whlierein the casein kinase 1 is a fragment or derivative of full length casein kinase 1 having the amino acid sequence set out between amino 30 acids 1 and 428 inclusive in SEQ ID NO: 1.
[24] 24. The method of claim 22 or claim 23, wherein the casein kinase 1 has greater than 80% sequence identity with full length casein kinase I having the amino acid 58 WO2005/001114 PCT/GB2004/002739 sequence set out between amino acids 1 and 428 inclusive of SEQ ID NO: 1.
[25] 25. The method of claim 22 or claim 23, wherein the 5 nucleic acid molecule encoding the casein kinase 1 is capable of hybridising under stringent conditions to a nucleic acid molecule encoding full length casein kinase 1 having the amino acid sequence set out in SEQ ID NO: 1. 10
[26] 26. The method of any one of claims 21 to 25, wherein the tau protein is paired helical filament tau.
[27] 27. The method of any one of claims 21 to 24, wherein the tau protein is a fragment or derivative of full 15 length tau protein having the amino acid sequence set out between amino acids 1 and 441 inclusive in SEQ ID NO: 3.
[28] 28. The method of any one of claims 21 to 27, wherein the tau protein has greater than 80% sequence identity 20 with full tau protein having the amino acid sequence set out between amino acids 1 and 441 inclusive in SEQ ID NO: 3.
[29] 29. The method of any one of claims 21 to 28, wherein a 25 nucleic acid molecule encoding the tau protein is capable of hybridising under stringent conditions to a nucleic acid molecule encoding full length tau protein having the amino acid sequence set out in SEQ ID NO: 3.
[30] 30 30. The method of any one of claims 21 to 29, wherein the casein kinase 1 phosphorylates tau protein at one or more sites selected from the group consisting of (S46/T50), S113, S131, T149, T169, S184, S208, (S210/T212), S214, S237, S238, S241, S258, S262, T263, 59 WO 2005/001114 PCT/GB2004/002739 S285, S289, S305, S341, S352, S356, T361, T373, T386, (S412/S413/T414), S416, S433 and S435 of tau protein.
[31] 31. The method of claim 30, wherein the sites of the tau 5 protein are selected from S262 and/oir S356.
[32] 32. The method of claim 30, wherein the sites of the tau protein at one or more sites selected from the group consisting of S113, S258, S289, S416, 5433 and S435. 10
[33] 33. The method of any one of claims 21 to 32, wherein the method comprises determining the effect of contacting the candidate substance(s) with a combination of kinases, simultaneously or sequentially applied to the candidate 15 substances and casein kinase 1.
[34] 34. The method of claim 33, wherein the combination of kinases comprises casein kinase 1 (CK1) in combination with one or more of casein kinase 2 (CK2), protein kinase 20 A (PKA), glycogen synthase kinase 3a (GSK-3a) or glycogen synthase kinase 3P (GSK-30).
[35] 35. The method of claim 33, wherein the combination of kinases comprises casein kinase 1 (CKl) in combination 25 with PKA and GSK-3.
[36] 36. The method of any one of claims 21 to 35, wherein the method comprises determining in step (b) whether, and optionally the extent to which, the candidate substance 30 inhibits the phosphorylation of a substrate by the casein kinase 1.
[37] 37. The method of claim 36, wherein the substrate of casein kinase 1 is not a tau protein or a fragment 60 WO2005/001114 PCT/GB2004/002739 thereof.
[38] 38. The method of claim 36 or claim 37 , wherein the method further comprises confirming whether a candidate 5 substance selected in an initial screen has the property of inhibiting the phosphorylation of the tau protein under conditions in which the casein kiLnase 1 is capable of phosphorylating the site(s) of the tau protein in the absence of the candidate substance. 10
[39] 39. The method of any one of claims 21 to 38, wherein the step of determining the presence, absence or extent of phosphorylation at one or more sites of the tau protein employs mass spectroscopy or a site specific 15 recognition agent which is capable of distinguishing between a phosphorylated and a non-phosphorylated site.
[40] 40. The method of claim 39, wherein the site specific recognition agent is a monoclonal antibody. 20
[41] 41. The method of any, one of claims 21 to 40, wherein the screening is carried out in a multiplex assay employing a solid phase on which a plurality of substrates are immobilised. 25
[42] 42. The method of claim 41, wherein the substrates correspond to phosphorylation sites of tau protein.
[43] 43. The method of any one of claims 21 to 42, the method 30 comprising having identified a candidate substance as an inhibitor of casein kinase 1, the further step of optimising the structure of the candidate substance.
[44] 44. A method which comprises having idenxitified a 61 WO 2005/001114 PCT/GB2004/002739 candidate substance by the method of any one of claims 21 to 43, the further step of manufacturing the substance and/or formulating it in pharmaceutical composition. 5
[45] 45. A method of preparing a pharmaceutical composition or medicament, the method comprising: (i) identifying a casein kinase a inhibitor according to any one of claims 1 to 43; (ii) optimising the structure of the casein kinase 1 10 inhibitor; and (iii) preparing the pharmaceutical -composition or medicament containing the optimised casein kinase 1 inhibitor. 15
[46] 46. A substance obtainable by the method of any one of claims 1 to 43.
[47] 47. Use of a substance of claim 46 for the preparation of a medicament for the treatment of a tauopathy. 20
[48] 48. The use of claim 47, wherein the tauopathy is Alzheimer's disease, frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy (PSP), Pick's disease, 25 corticobasal degeneration, multisystern atrophy (MSA), neurobasal degeneration with iron accumulation, type 1 (Hallervorden-Spatz), argyrophilic grain dementia, Down's syndrome, diffuse neurofibrillary tangles with calcification, dementia pugilistica, Gerstmann 30 Strdussler-Scheinker disease, myotonic dystrophy, Niemann-Pick disease type C, progressive subcortical gliosis, prion protein cerebral amyloid angiopathy, tangle only dementia, postencephalitic parkinsonism, subacute sclerosing panencephalitis, Creutzfeldt-Jakob 62 WO2005/001114 PCT/GB2004/002739 disease, amyotrophic lateral sclerosis/parkirsonism dementia complex, non-Guamanian motor neuron disease with neurofibrillary tangles/dementia, and Parkinson's disease. 5
[49] 49. Use of fyn, or a nucleic acid molecule encoding fyn, for screening for candidate compounds which are capable of (a) inhibiting the activity of fyn in phosphorylating a tau protein at a position corresponding to Y394 or (b) 10 binding to fyn to inhibit its interaction with a tau protein at Y394. 48. A method of screening for substances which are capable of inhibiting the phosphorylation of a tau 15 protein at a phosphorylation site at position Y394 by fyn, the method comprising: (a) contacting at least one candidate substance, the tau protein and fyn under conditions in which the fyn is capable of phosphorylating position Y394 cf the tau 20 protein in the absence of the candidate substance; (b) determining whether, and optionally the extent to which, the candidate substance inhibits the phosphorylation of the tau protein at position Y394 of the tau-protein by fyn; and, 25 (c) selecting the candidate substance which inhibits phosphorylation of the tau protein at position Y394. 49. A method of screening for substances which are 30 capable of inhibiting phosphorylation by a kinase at one or more of the site(s) of a tau protein selected from the group consisting of 868, T69, T71, (T111/S113), S191, S258, S289, (T414/S416), T427, S433, S435 and Y394, the method comprising: 63 WO2005/001114 PCT/GB2004/002739 (a) contacting at least one candidate substance, a tau protein which comprises one or more of the phosphorylation sites and a kinase which is capable of phosphorylating the tau protein under conditions in which 5 the kinase is capable of phosphorylating one or more of the sites of the tau protein in the absence of the candidate substance; (b) determining whether, and optionally the extent to which, the candidate substance inhibits the 10 phosphorylation of the tau protein at one or more sites of the tau protein; and, (c) selecting the candidate substance which inhibits phosphorylation of the tau protein at one or more of the sites. 15
[50] 50. A method of screening for substances which are capable of promoting dephosphorylation of a tau protein by a phosphatase at one or more of the site (s) of a tau protein selected from the group consisting of SG8, T69, 20 T71, (T11/S113), S191, S258, S289, (T414/S416), T427, S433, S435 and Y394, the method comprising: (a) contacting at least one candidate substance, a tau protein comprising one or more the phosphorylation site and a phosphatase which is capable of 25 dephosphorylating the tau protein under conditions in which the phosphatase is capable of dephosphorylating the site(s) of the tau protein in the absence of the candidate substance; (b) determining whether, and optionally the extent 30 to which, the candidate substance promotes the dephosphorylation of the tau protein at one or more sites of the tau protein; and, (c) selecting the candidate substance which promotes dephosphorylation of the tau protein at one or 64 WO 2005/001114 PCT/GB2004/002739 more of the sites. 65

类似技术:

---

公开号 | 公开日 | 专利标题

---

CA2848433C|2017-01-10|Screening methods

---

US20160186233A1|2016-06-30|Screening methods using fyn in combination with tau protein

---

Grønborg et al.2002|A mass spectrometry-based proteomic approach for identification of serine/threonine-phosphorylated proteins by enrichment with phospho-specific antibodies: identification of a novel protein, Frigg, as a protein kinase A substrate

---

Ingham et al.2005|WW domains provide a platform for the assembly of multiprotein networks

---

von Nandelstadh et al.2009|A class III PDZ binding motif in the myotilin and FATZ families binds enigma family proteins: a common link for Z-disc myopathies

---

US6207393B1|2001-03-27|Inhibition of intracellular signal transduction by 14-3-3-binding peptides

---

US8748119B2|2014-06-10|Methods for determining calcineurin activity, and uses in predicting therapeutic outcomes

---

Kwiek et al.2006|PITK, a PP1 targeting subunit that modulates the phosphorylation of the transcriptional regulator hnRNP K

---

WO2002024941A2|2002-03-28|Protein kinase regulation

---

KR20060065695A|2006-06-14|A method for the identification of irs protein kinase inhibitors or agonists

---

AU1680102A|2002-08-29|Assays for assessing AB-TAU aggregation

---

Class et al.2013|Inventors: Malcolm Ward | Proteome Science Plc | Helen Byers | King'S College London | Brian Henry Anderton | Pascal Derkinderen | Christipher Hugh Reynolds | Ritchie Williamson | Assignees: KING'S COLLEGE LONDON PROTEOME SCIENCES PLC

---

GB2362952A|2001-12-05|Assay method to determine compounds affecting DNA binding by ATM.

同族专利:

---

公开号 | 公开日

---

JP5688747B2|2015-03-25|

---

EP1636375B1|2008-08-13|

---

ES2313032T3|2009-03-01|

---

US8822171B1|2014-09-02|

---

WO2005001114A3|2005-03-31|

---

CA2848433A1|2005-01-06|

---

CA2527437A1|2005-01-06|

---

EP1636375A2|2006-03-22|

---

WO2005001114A2|2005-01-06|

---

CA2848433C|2017-01-10|

---

GB0314943D0|2003-07-30|

---

JP2012045002A|2012-03-08|

---

US20150051097A1|2015-02-19|

---

JP2007527210A|2007-09-27|

---

AT404692T|2008-08-15|

---

DK1636375T3|2008-12-15|

---

CA2527437C|2016-08-02|

---

AU2004252273B2|2011-04-28|

---

DE602004015791D1|2008-09-25|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

GB9316727D0|1993-08-12|1993-09-29|Inst Of Psychiatry|Models of alzheimers's disease|

---

AU1831195A|1994-01-13|1995-08-01|Research Foundation For Mental Hygiene, Inc.|Methods and compositions for treatment and diagnosis of alzheimer disease and other disorders|

---

US6057117A|1996-04-04|2000-05-02|Chiron Corporation|Identification and use of selective inhibitors of glycogen synthase kinase 3|

---

US6593512B1|1999-03-03|2003-07-15|Cognosci, Inc.|Transgenic mouse expressing human tau gene|

---

EP1209969A2|1999-08-31|2002-06-05|RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH &amp; INDUSTRIAL DEVELOPMENT LTD.|Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders|

---

US6503914B1|2000-10-23|2003-01-07|Board Of Regents, The University Of Texas System|Thienopyrimidine-based inhibitors of the Src family|

---

US20020172990A1|2002-02-19|2002-11-21|Thomas Curran|Cyclin dependent kinase 5 phosphorylation of disabled 1 protein|

---

GB0314943D0|2003-06-25|2003-07-30|Proteome Sciences Plc|Screening methods|GB0314943D0|2003-06-25|2003-07-30|Proteome Sciences Plc|Screening methods|

---

EP1794313B1|2004-06-21|2013-05-15|Proteome Sciences Plc|Screening methods using c-abl, fyn and syk in combination with tau protein|

---

JP4522910B2|2005-05-30|2010-08-11|株式会社日立ハイテクノロジーズ|Mass spectrometry method and mass spectrometer|

---

US9532980B2|2006-10-25|2017-01-03|The Rockefeller University|Methods for the treatment of A-β related disorders and compositions therefor|

---

WO2009101942A1|2008-02-12|2009-08-20|Takeda Pharmaceutical Company Limited|Screening method|

---

GB0903913D0|2009-03-06|2009-04-22|Medical Res Council|Compositions and methods|

---

WO2012080727A2|2010-12-14|2012-06-21|Electrophoretics Limited|Casein kinase 1deltainhibitors|

---

WO2014055413A2|2012-10-02|2014-04-10|Bloodcenter Research Foundation|A method of providing cellular therapy using modified natural killer cells or t lymphocytes|

---

AU2015204566A1|2014-01-09|2016-08-25|Intra-Cellular Therapies, Inc.|Organic compounds|

---

US10863094B2|2017-07-17|2020-12-08|Apple Inc.|Camera with image sensor shifting|

---

US11122205B1|2018-09-14|2021-09-14|Apple Inc.|Camera actuator assembly with sensor shift flexure arrangement|

法律状态:
2011-08-25| FGA| Letters patent sealed or granted (standard patent)|

---

2020-01-30| MK14| Patent ceased section 143(a) (annual fees not paid) or expired|

优先权:

---

申请号 | 申请日 | 专利标题

---

GBGB0314943.2A|GB0314943D0|2003-06-25|2003-06-25|Screening methods|

---

GB0314943.2||2003-06-25||

---

PCT/GB2004/002739|WO2005001114A2|2003-06-25|2004-06-25|Screening methods|

---